Antithrombotic agents in coronary artery disease.
Cairns
J A
JA
Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Théroux
P
P
Lewis
H D
HD
Ezekowitz
M
M
Meade
T W
TW
Sutton
G C
GC
D000789:Angina, Unstable / Q000150:complications*; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D003327:Coronary Disease / Q000150:complications* / Q000517:prevention & control; D003328:Coronary Thrombosis / Q000517:prevention & control; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications* / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011322:Primary Prevention; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D001241:Aspirin